Investing.com - Mesoblast (NASDAQ:MESO) reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of -0.1 on revenue of 1.7M. Analysts polled by Investing.com anticipated EPS of -0.03 on revenue of 42M.
Mesoblast shares are down 63% from the beginning of the year, still down 49.06% from its 52 week high of 21.22 set on August 17. They are under-performing the PSI 20 which is down 24.82% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings beat by J&J on October 13, who reported EPS of 2.2 on revenue of 21.08B, compared to forecasts EPS of 1.98 on revenue of 20.2B.
Pfizer had beat expectations on Tuesday with third quarter EPS of 0.72 on revenue of 12.13B, compared to forecast for EPS of 0.69 on revenue of 12.31B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar